Sophie Postel‐Vinay
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 24
- PARP inhibition in cancer therapy 15
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 30
-
- Lung Cancer Treatments and Mutations 19
- Immunology top 2%
- Statistics and Probability top 1%
- Statistical Methods in Clinical Trials 13
-
- DNA Repair Mechanisms 11
- Cancer-related gene regulation 9
- Epigenetics and DNA Methylation 9
- Co-authors
- Jean‐Charles SoriaAurélien MarabelleSandrine AspeslaghChristophe MassardAntoine HollebecqueStéphane ChampiatDaphné MorelSamy Ammari
- Journals
- Nature Communications (2 papers)Nature Genetics (1 paper)Journal of Clinical Oncology (11 papers)
- Partner nations
- FranceUnited KingdomUnited States
In The Last Decade
Sophie Postel‐Vinay
109 papers receiving 5.6k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 3.2k
- Cancer Research 936
- Pulmonary and Respiratory Medicine 1.7k
- Immunology 951
- Statistics and Probability 271
Countries citing papers authored by Sophie Postel‐Vinay
This map shows the geographic impact of Sophie Postel‐Vinay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Postel‐Vinay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Postel‐Vinay more than expected).
Fields of papers citing papers by Sophie Postel‐Vinay
This network shows the impact of papers produced by Sophie Postel‐Vinay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Postel‐Vinay. The network helps show where Sophie Postel‐Vinay may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sophie Postel‐Vinay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 studybreakdown → | 2024 | 43 |
| 3 | 2023 | 2 | |
| 4 | 2023 | 19 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 1 | |
| 8 | 2021 | 71 | |
| 9 | 2020 | 63 | |
| 10 | 2020 | 5 | |
| 11 | 2020 | 5 | |
| 12 | 2018 | 106 | |
| 13 | 2018 | 41 | |
| 14 | 2018 | 1 | |
| 15 | Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1breakdown → | 2016 | 867 |
| 16 | 2016 | 59 | |
| 17 | 2016 | 15 | |
| 18 | 2015 | 1 | |
| 19 | 2014 | 60 | |
| 20 | 2010 | 69 |
About Sophie Postel‐Vinay
Sophie Postel‐Vinay is a scholar working on Oncology, Cancer Research and Statistics and Probability, having authored 117 papers that have together received 5.7k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (30 papers), Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (19 papers), PARP inhibition in cancer therapy (15 papers), Statistical Methods in Clinical Trials (13 papers), DNA Repair Mechanisms (11 papers), Cancer-related gene regulation (9 papers) and Epigenetics and DNA Methylation (9 papers). The work is most often cited by research in Oncology (3.2k citations), Cancer Research (936 citations) and Pulmonary and Respiratory Medicine (1.7k citations). Sophie Postel‐Vinay has collaborated with scholars based in France, United Kingdom and United States. Frequent co-authors include Jean‐Charles Soria, Aurélien Marabelle, Sandrine Aspeslagh, Christophe Massard, Antoine Hollebecque, Stéphane Champiat, Daphné Morel, Samy Ammari, Fabrice André and Laurent Dercle. Their work appears in journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.